JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: JK184 is a novel and potent Hedgehog (Hh) pathway inhibitor with IC50 of 30 nM in mammalian cells. JK184 can specially inhibit glioma (Gli)-dependent transcriptional activity in the Hedgehog (Hh) pathway in a dose dependent manner and showed great promise for cancer therapeutics. JK184 significantly inhibits proliferation of HUVECs with IC50 of 6.3 ug/mL after three days incubation. To evaluate anti-tumor effect of JK184, MTT assay is conducted in Panc-1 and BxPC-3 cells after administration with indicated concentrations of compounds, half maximal inhibitory concentration (IC50) of JK184 (23.7 ng/mL in anc-1 and 34.3 ng/mL in BxPC-3).
References: Nanoscale. 2015 Feb 14; 7(6):2609-24; Breast Cancer Res. 2014 Sep 25; 16(5):444.
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!